Subodh Verma




Please note: Dr. Verma will not take students in summer.

Dr. Subodh Verma is an internationally renowned cardiac surgeon-scientist and Professor at the University of Toronto. He is the current Canada Research Chair in Cardiovascular Surgery, having previously served as the Canada Research Chair in Atherosclerosis (2007-2017). Dr. Verma was recently awarded the 2021 Lister Prize in Surgery from the University of Toronto in recognition of his outstanding and continuing productivity of international stature. He is a past recipient of the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. He is an appointee of the American Association of Thoracic Surgeons (AATS) and a member of the College of New Scholars, Artists and Scientists, Royal Society of Canada. According to Google Scholar in April 2021, Dr. Verma has an h-index of 100 and his work has been cited over 50,000 times.

Dr. Verma has published extensively in highly impactful journals like the NEJM, Lancet, Circulation, JACC, Nature, and JCI. He is an Associate Editor of the European Heart Journal. Dr. Verma is an active contributor to Canadian clinical practice guidelines and co-authored the recently updated recommendations for atrial fibrillation, antiplatelet therapy, diabetes, and heart failure; he was a member of the 2018 AATS consensus guidelines committee on bicuspid aortic valve-related aortopathy. Dr. Verma has served in various capacities on the American Heart Association Council on Cardiovascular Surgery and Anesthesia since 2008.

Dr. Verma had/has leadership roles on 10 contemporary global heart failure trials – several of which have let to paradigm changes in how individuals all around the world who live with diabetes and heart failure are now managed. He founded and oversees the CardioLink platform at St Michael’s Hospital that is conducting cardiometabolic and surgically oriented RCTs and translational studies.

Dr. Verma leads a dynamic pre-clinical and translational research team that leverages pre-clinical disease models and clinical trial-derived data to identify novel mediators of cardiovascular and cardiometabolic disease as well as answer timely and relevant healthcare questions. His research has yielded 2 United States patents and is supported by several national peer-reviewed grants.


Recent Publications

  1. Dhingra, NK, Mazer, CD, Connelly, KA, Verma, S. Chronic heart failure management in adult patients with congenital heart disease. Curr Opin Cardiol. 2023; :. doi: 10.1097/HCO.0000000000001011. PubMed PMID:36656602 .
  2. Krishnaraj, A, Bakbak, E, Teoh, H, Bhatt, DL, Quan, A, Puar, P et al.. Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease. Med (N Y). 2023; :. doi: 10.1016/j.medj.2022.12.008. PubMed PMID:36630964 .
  3. Cosentino, F, Marx, N, Verma, S. The year in cardiovascular medicine 2022: the top 10 papers in diabetes and metabolic disorders. Eur Heart J. 2023; :. doi: 10.1093/eurheartj/ehac780. PubMed PMID:36587943 .
  4. Mistry, N, Hare, GMT, Shehata, N, Belley-Cote, E, Papa, F, Kramer, RS et al.. Transfusion Thresholds for Acute Coronary Syndromes-Insights From the TRICS-III Randomized Controlled Trial, Systematic Review, and Meta-Analysis. J Am Heart Assoc. 2023;12 (1):e028497. doi: 10.1161/JAHA.122.028497. PubMed PMID:36565203 .
  5. Khan, MS, Butler, J, Anker, SD, Filippatos, G, Ferreira, JP, Pocock, SJ et al.. Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause. J Am Heart Assoc. 2023;12 (1):e027652. doi: 10.1161/JAHA.122.027652. PubMed PMID:36565199 .
  6. Marx, N, Husain, M, Lehrke, M, Verma, S, Sattar, N. GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. Circulation. 2022;146 (24):1882-1894. doi: 10.1161/CIRCULATIONAHA.122.059595. PubMed PMID:36508493 .
  7. Anker, SD, Butler, J, Usman, MS, Filippatos, G, Ferreira, JP, Bocchi, E et al.. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved. Nat Med. 2022;28 (12):2512-2520. doi: 10.1038/s41591-022-02041-5. PubMed PMID:36471037 PubMed Central PMC9800272.
  8. Verma, S, Bhatta, M, Davies, M, Deanfield, JE, Garvey, WT, Jensen, C et al.. Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials. EClinicalMedicine. 2023;55 :101737. doi: 10.1016/j.eclinm.2022.101737. PubMed PMID:36467859 PubMed Central PMC9713290.
  9. Inzucchi, SE, Claggett, BL, Vaduganathan, M, Desai, AS, Jhund, PS, de Boer, RA et al.. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2022;10 (12):869-881. doi: 10.1016/S2213-8587(22)00308-4. PubMed PMID:36372069 .
  10. Verma, S, Dhingra, NK, Butler, J, Anker, SD, Pedro Ferreira, J, Filippatos, G et al.. Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled. Circulation. 2023;147 (1):101-104. doi: 10.1161/CIRCULATIONAHA.122.062644. PubMed PMID:36342827 .
Search PubMed

Affiliations & Other Activities

  • Cardiac Surgeon, Division of Cardiology , St. Michael’s Hospital
  • Professor of Surgery and Pharmacology & Toxicology, University of Toronto
  • Canada Research Chair in Cardiovascular Surgery